IS7831A - Bóluefni - Google Patents

Bóluefni

Info

Publication number
IS7831A
IS7831A IS7831A IS7831A IS7831A IS 7831 A IS7831 A IS 7831A IS 7831 A IS7831 A IS 7831A IS 7831 A IS7831 A IS 7831A IS 7831 A IS7831 A IS 7831A
Authority
IS
Iceland
Prior art keywords
vaccine
Prior art date
Application number
IS7831A
Other languages
English (en)
Inventor
Brett Sara
Andrew Hamblin Paul
Ogilvie Louise
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7831A publication Critical patent/IS7831A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IS7831A 2002-11-15 2005-04-28 Bóluefni IS7831A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine
PCT/EP2003/012793 WO2004046175A1 (en) 2002-11-15 2003-11-13 Vaccine

Publications (1)

Publication Number Publication Date
IS7831A true IS7831A (is) 2005-04-28

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
IS7830A IS7830A (is) 2002-11-15 2005-04-28 Bóluefni gegn lifrarbólgu C veiru (HCV)
IS7831A IS7831A (is) 2002-11-15 2005-04-28 Bóluefni

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS7830A IS7830A (is) 2002-11-15 2005-04-28 Bóluefni gegn lifrarbólgu C veiru (HCV)

Country Status (21)

Country Link
US (4) US20060135451A1 (is)
EP (2) EP1560844A1 (is)
JP (2) JP2006518331A (is)
KR (2) KR20050085010A (is)
CN (2) CN1738834A (is)
AR (1) AR041964A1 (is)
AU (2) AU2003288084A1 (is)
BR (2) BR0316244A (is)
CA (2) CA2504654A1 (is)
CO (1) CO5700833A2 (is)
GB (1) GB0226722D0 (is)
IS (2) IS7830A (is)
MA (2) MA27699A1 (is)
MX (2) MXPA05005202A (is)
NO (2) NO20052136L (is)
NZ (2) NZ539999A (is)
PL (2) PL376967A1 (is)
RU (2) RU2323744C2 (is)
TW (1) TW200502246A (is)
WO (2) WO2004046175A1 (is)
ZA (2) ZA200503803B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2006044923A2 (en) 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
ES2551113T3 (es) * 2006-01-04 2015-11-16 Glaxosmithkline Biologicals S.A. Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC
WO2007101657A1 (en) * 2006-03-09 2007-09-13 Transgene S.A. Hepatitis c virus non structural fusion protein
AU2007345682B2 (en) * 2006-07-27 2013-07-18 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
JP2011529077A (ja) * 2008-07-24 2011-12-01 アデュロ バイオテック Ｃ型肝炎の治療のための組成物および方法
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
RU2684211C2 (ru) * 2013-02-21 2019-04-04 Тёрнстоун Лимитед Партнершип Композиция вакцины

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
AU701747B2 (en) * 1994-10-05 1999-02-04 Apollon, Inc. Hepatitis virus vaccines
AU5924396A (en) * 1995-05-22 1996-12-11 Bionova Corporation Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
CA2257137A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
CA2379235A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services, Centers For Disease Co Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
EP1232267B1 (en) * 1999-10-27 2013-03-20 Novartis Vaccines and Diagnostics, Inc. Activation of hcv-specific t cells
CN101684146A (zh) * 1999-11-24 2010-03-31 诺华疫苗和诊断公司 新颖的hcv非结构多肽
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2005113691A (ru) 2006-01-27
PL376882A1 (pl) 2006-01-09
NO20052136D0 (no) 2005-05-02
RU2005113692A (ru) 2006-01-27
NO20052149D0 (no) 2005-05-02
KR20050085009A (ko) 2005-08-29
JP2006518331A (ja) 2006-08-10
NO20052149L (no) 2005-07-11
ZA200503803B (en) 2006-08-30
WO2004046175A1 (en) 2004-06-03
AU2003288072A1 (en) 2004-06-15
NO20052136L (no) 2005-07-11
GB0226722D0 (en) 2002-12-24
CO5700833A2 (es) 2006-11-30
PL376967A1 (pl) 2006-01-23
ZA200503802B (en) 2006-08-30
RU2323744C2 (ru) 2008-05-10
US20090232847A1 (en) 2009-09-17
IS7830A (is) 2005-04-28
US20090104231A1 (en) 2009-04-23
MA27700A1 (fr) 2006-01-02
MXPA05005202A (es) 2006-01-27
US20060246090A1 (en) 2006-11-02
EP1560845A1 (en) 2005-08-10
JP2006524181A (ja) 2006-10-26
MA27699A1 (fr) 2006-01-02
BR0316244A (pt) 2005-10-04
AU2003288084A1 (en) 2004-06-15
RU2363492C2 (ru) 2009-08-10
US20060135451A1 (en) 2006-06-22
CN1738833A (zh) 2006-02-22
NZ539999A (en) 2008-03-28
EP1560844A1 (en) 2005-08-10
BR0316291A (pt) 2005-10-11
MXPA05005203A (es) 2006-01-27
CN1738834A (zh) 2006-02-22
NZ539998A (en) 2008-04-30
CA2504654A1 (en) 2004-06-03
AR041964A1 (es) 2005-06-01
WO2004046176A1 (en) 2004-06-03
TW200502246A (en) 2005-01-16
CA2504715A1 (en) 2004-06-03
KR20050085010A (ko) 2005-08-29

Similar Documents

Publication Publication Date Title
IS7831A (is) Bóluefni
NO20050132D0 (no) Vaksinesammensetning
IS7547A (is) Ónæmisvaldandi samsetningar
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
ATE318817T1 (de) Aza-arylpiperazine
ATE427876T1 (de) Luftkissenboot
DE50212349D1 (de) Hirurgie
DK1427444T3 (da) West-nil-vaccine
NO20033882L (no) Vaksine
ATE349458T1 (de) Etonogestrelester
IS8325A (is) Bóluefni
DE60328408D1 (de) Impfstoff
ATA1572002A (de) Managementspleisskassette
NO20051561D0 (no) Vaksine
DE50310481D1 (de) Röntgenstativ
DE60320941D1 (de) Amidoacetonitrilderivate
DE60312227D1 (de) Klebwalzereiniger
ATA4142004A (de) Trägerverbau
ATE469773T1 (de) Zugöse
ATA19152002A (de) Hubkupplung
ATE396192T1 (de) N-sulfonylaminothiazole
DE60320425D1 (de) Ostertagia-impfstoff
DE10244834B8 (de) Suszeptometer
DE50209283D1 (de) Tropfbewässerungsrohr